Agreement with Apres Owner, LLC. $176 million.

✦Braemar Hotels & Resorts signed a $176 million agreement with Apres Owner, LLC, potentially indicating a significant acquisition or financing transaction that could impact the REIT's portfolio expansion or capital structure.

Terminated TR-Beta Program pursuant to the terms of the License with VALLEY BLVD. effective May 4, 2026.

✦The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.

Terminated Securitization Facility and loan.

✦I need more specific information from the filing to determine the termination reason and company name. Without knowing which company is involved, the termination basis (breach, mutual consent, regulatory action, or expiration), and whether early termination carries financial penalties or debt consequences, I cannot provide a meaningful one-sentence analysis. Please provide the company name and details about the termination circumstances.

Agreement with Clovis Davis Pharmaceuticals, LLC.

✦Evofem Biosciences entered into a material agreement with Clovis Davis Pharmaceuticals, though specific terms remain undisclosed in this filing.

On April 27, 2026, the Board of Directors of Visium Technologies, Inc. ( PTNA ), a wholly owned subsidiary organized as a C-Corporation under the General Corporation Law of the State of Delaware.

✦Visium Technologies reorganized its subsidiary PTNA as a Delaware C-Corporation, a structural change that may have tax or operational implications for the parent company and its investors.

Entered into Amended and Restated Loan Arrangement and Reimbursement and Spons.

✦Rivian Automotive restructured its loan arrangement and sponsorship reimbursement terms, potentially improving financial flexibility and clarifying obligations with lenders or sponsors during its scaling operations.

The dividend will be paid on or about June 5, 2026 to stockholders of record at the close of business on May 22, 2026.

✦Bank of the James Financial Group will distribute a dividend to shareholders on June 5, 2026, benefiting those holding shares through the May 22 record date.

On April 23, 2026, our Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $400 million of the Company s common stock. Repurchases may be made from time to time through open market purchases, privately negotiated transactions, block purchases, accelerated share repurchase agreements, or other methods, including under Rule 10b5 1 trading plans, in accordance with applicable securities laws.

✦Floor & Decor's Board authorized a $400 million share buyback program, signaling management confidence in the stock's value and potentially supporting the share price through capital returns.

April 2026 Distributions On April 30, 2026, Starwood Real Estate Income Trust, Inc. These distributions will be paid in cash or reinvested in shares of the Company s common stock for stockholders participating in the Company s distribution reinvestment plan.

✦Starwood Real Estate Income Trust announced April 2026 cash distributions with a reinvestment option, allowing shareholders to receive dividends in cash or automatically reinvest in common stock shares.

Food and Drug Administration (FDA) has approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer s disease. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

✦FDA approval of Axsome's AUVELITY for Alzheimer's dementia-related agitation expands the company's commercial opportunity in neurology and validates its therapeutic approach for this patient population.

The Company also announced in the Press Release that its Board of Directors has declared a cash dividend of $0.50 per share on its Common Stock, which represents an 11% increase from prior quarterly dividends on its Common Stock. A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

✦AIG's board increased its quarterly dividend by 11% to $0.50 per share, signaling confidence in the insurer's financial strength and improved capital position to shareholders.

On April 30, 2026, the Company's board of directors (the "Board") declared a regular quarterly dividend of $0.13 per share on the outstanding Class A common stock. The regular quarterly dividend will be payable on May 26, 2026, to stockholders of record as of the close of business on May 12, 2026.

✦Ryan Specialty Holdings declared a quarterly dividend of $0.13 per share payable May 26, 2026, signaling management confidence in sustained cash generation and shareholder capital return.

Agreement with Judith Ripka Designs, LLC. $2.3 million.

✦Xcel Brands agreed to a $2.3 million transaction with Judith Ripka Designs, likely expanding its jewelry portfolio and generating near-term revenue through this established designer brand partnership.

( HCW Biologics or the Company ) convened a Special Meeting of its Stockholders ( Special Meeting ). At that time, there were not present or represented by proxy a sufficient number of shares of the Company s Common Stock to constitute a quorum.

✦HCW Biologics failed to achieve quorum at its special stockholder meeting, preventing any votes on proposed matters and potentially delaying critical corporate actions.

On April 30, 2026, the Company announced that its Board of Directors has authorized management to repurchase up to an additional $400 million of the Company s common stock (the Share Repurchase Program ). The full text of the press release announcing the Share Repurchase Program is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

✦Universal Display Corporation authorized a $400 million share repurchase program, signaling management confidence in OLED's valuation and potentially supporting stock price through reduced share count.

Quarterly Common and Preferred Stock Dividend. At the meeting of the Board of Directors (the Board ) of Western Alliance Bancorporation held on April 30, 2026, the Board declared a quarterly cash dividend of $0.42 per share of common stock.

✦Western Alliance Bancorporation's board declared a $0.42 per share quarterly common dividend, maintaining shareholder distributions and signaling confidence in the bank's financial stability and cash flow generation.

On April 30, 2026, the Company issued the news release attached hereto as Exhibit 99.2 announcing that the Company s board of directors authorized the repurchase of up to $500 million of the Company s outstanding shares of common stock.

✦Builders FirstSource authorized a $500 million share repurchase program, signaling management confidence and providing potential support for the stock price through reduced share count.

Entered into Share Purchase and Transfer Agreement. $19.5 million.

✦Brand Engagement Network, Inc. entered into a Share Purchase and Transfer Agreement valued at $19.5 million, potentially indicating a significant equity transaction or capital raise that could affect shareholder dilution and company valuation.

Entered into Exchange Agreement.

✦GlucoTrack, Inc. entered into an exchange agreement that could affect shareholder equity structure, though full details on the counterparty and consideration remain unclear from this brief disclosure.

On April 30, 2026, the Company issued a press release announcing the completion of its End-of-Phase 2 meeting with the FDA and the receipt of guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company s investigational first-in-class 12-LOX inhibitor for HIT. The meeting with the FDA provided critical guidance on protocol design, study population, dosing, background therapy, exposure, the safety database, and the primary endpoint of new or worsening thrombotic events.

✦Cadrenal Therapeutics completed its FDA End-of-Phase 2 meeting for CAD-1005, receiving guidance on Phase 3 trial design for this heart inflammation treatment, potentially accelerating development timelines.

On April 29, 2026, the Board of Directors of Escalade approved a quarterly dividend of fifteen and twenty-five hundredths cents $0.1525 per share would be paid to all shareholders of record on July 6, 2026 and disbursed on July 13, 2026.

✦Escalade declared a quarterly dividend of $0.1525 per share payable July 13, 2026, providing shareholders with regular income distributions from the sporting goods company.

On April 30, 2026, the Company issued a press release announcing that its Board of Directors authorized the repurchase of up to $20 million in shares (the Shares ) of the Company s common stock, par value $0.001, which are listed for trading on Cboe Canada. The Company can purchase up to an aggregate of 18,219,090 Shares (representing 5% of the issued and outstanding Shares of the Company at the time of the authorization), subject to the $20 million limit.

✦Verano Holdings authorized a $20 million share buyback program covering up to 5% of outstanding shares, signaling management confidence and potentially supporting the stock price.

Entered into Purchase Agreement with Vistance, inc. $1.846 billion.

✦Belden Inc. agreed to acquire Vistance, Inc. for $1.846 billion, expanding its portfolio through this significant strategic purchase.

On April 30, 2026, the Company announced a cash dividend of $0.23 per Class A Share. The dividend is payable on May 27, 2026, to holders of record as of the close of business on May 13, 2026.

✦Blue Owl Capital declared a $0.23 per share quarterly dividend payable May 27, 2026, to shareholders of record as of May 13, 2026.

Other Events Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center Telomir Pharmaceuticals, Inc.

✦Telomir Pharmaceuticals gained FDA clearance to begin human trials of Telomir-Zn for triple-negative breast cancer, enabling a Phase 1/2 study launch in mid-2026 at a major academic institution.

The Acquisition was primarily financed through borrowings under Kadant's revolving credit facility. At closing, the company names were changed to Kadant Profil GmbH Co KG and Kadant Profil Verwaltungs GmbH (collectively, Kadant Profil).

✦Kadant Inc. financed its acquisition of Profil through revolving credit borrowings, rebranding the acquired entities as Kadant Profil subsidiaries to integrate the purchase.

Entered into Equity Purchase Agreement with Ohio River Partners Holdco LLC. $1.5 billion.

✦Marathon Digital Holdings secured $1.5 billion in equity financing from Ohio River Partners Holdco LLC, providing substantial capital for Bitcoin mining expansion and operational growth.

The information in this Current Report on Form 8-K with respect to

✦I'd be happy to help, but the summary appears to be incomplete. Could you please provide the full summary text describing the material event or announcement that Artificial Intelligence Technology Solutions Inc. (AITX) disclosed? This will allow me to write an accurate one-sentence analysis for investors.

( Genprex or the Company ) issued a press release in which it announced that the Israel Patent Office ( ILPO ) has granted Genprex a patent covering the use of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. The press release noted that this strategic expansion builds upon the Company s existing intellectual property in numerous major markets worldwide and underscores the scientific innovation behind REQORSA.

✦Genprex secured an Israeli patent for its Reqorsa gene therapy combined with PD-1 antibodies in cancer treatment, strengthening its intellectual property portfolio and competitive position in immunotherapy.

This Repurchase Program replaces the Company s prior authorization to repurchase up to $50 million of the Company s outstanding common stock. Any share repurchases under the Repurchase Program will be made in accordance with applicable securities laws in either open market or privately negotiated transactions.

✦Vistance Networks increased its share repurchase authorization, replacing the prior $50 million program, allowing management flexibility to buy back stock in open market or private transactions.

On April 30, 2026, Textron announced its intent to separate its Industrial segment, composed of Kautex and Textron Specialized Vehicles, from the Company s core aerospace and defense businesses to enhance its strategic and operational focus and drive long-term value for stakeholders. Textron intends to explore multiple paths to effect the planned separation of its Industrial segment, including but not limited to a sale of the Industrial businesses or a tax-free separation into a standalone, publ

✦Textron plans to separate its Industrial segment (Kautex and Specialized Vehicles) from its aerospace-defense core through sale or spin-off to enhance strategic focus and shareholder value.